


TRISTAN experimental medicine study:
Results on the primary objective

Internal report
TRISTAN work package 2
26 sept 2023



Rifampicin effect size (%)
on hepatocellular uptake (k_{he} , left) and biliary excretion (k_{bh} , right) of Gadoxetate.
The boxplot shows median, interquartile range and 95 percent range.



Rifampicin effect size and absolute values
of hepatocellular uptake (k_{he}) and biliary excretion (k_{bh})
of Gadoxetate


	count	mean	std	min	25%	50%	75%	max
k _{he} effect size (%)	8.0	-92.9	1.8	-94.6	-94.5	-93.4	-91.9	-90.1
k _{he} baseline (mL/min/100ml)	10.0	19.12	4.69	13.53	15.23	19.82	20.64	28.33
k _{he} rifampicin (mL/min/100ml)	8.0	1.38	0.42	0.74	1.15	1.4	1.5	2.19
k _{bh} effect size (%)	8.0	-48.1	27.7	-77.8	-63.9	-55.5	-43.5	8.9
k _{bh} baseline (mL/min/100ml)	10.0	1.97	0.75	0.68	1.61	1.99	2.53	3.01
k _{bh} rifampicin (mL/min/100ml)	8.0	0.95	0.36	0.5	0.71	0.82	1.3	1.46

Individual values
for hepatocellular uptake (k_{he} , left) and biliary excretion (k_{bh} , right) of Gadoxetate
at baseline (left of plot) and after administration of rifampicin (right of plot).



Intra-day changes
in hepatocellular uptake (k_{he} , top row) and biliary excretion (k_{bh} , bottom row) of Gadoxetate
at baseline (left column) and after administration of rifampicin (right column).
Full lines connect values taken in the same subject at the same day.

Baseline



Rifampicin

